Who are Anaferon for Children's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): herbal immunomodulator, Glatiramer acetate (GA), ferrous gluconate with lactoferrin, Glatiramer acetate (Copaxone), injectable MS DMT, Ixazomib plus low-dose lenalidomide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anaferon-for-children.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anaferon for Children — Competitive Intelligence Brief

Anaferon for Children (Anaferon for Children) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology / Virology.

marketed Immunomodulator Immunology / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Anaferon for Children (Anaferon for Children) — Materia Medica Holding. Anaferon for Children is an immunomodulatory agent that stimulates interferon production and enhances innate immune responses to combat viral infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anaferon for Children TARGET	Anaferon for Children	Materia Medica Holding	marketed	Immunomodulator
herbal immunomodulator	herbal immunomodulator	Tatyasaheb Kore Dental College	marketed	Herbal immunomodulator
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
ferrous gluconate with lactoferrin	ferrous gluconate with lactoferrin	Ain Shams University	marketed	Iron supplement with immunomodulatory adjuvant
Glatiramer acetate (Copaxone)	Glatiramer acetate (Copaxone)	Federal University of São Paulo	marketed	Immunomodulator; disease-modifying therapy (DMT)	T cell receptor (indirect); myelin basic protein mimic
injectable MS DMT	injectable MS DMT	Biogen	marketed	Immunomodulator (disease-modifying therapy)
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anaferon for Children — Competitive Intelligence Brief. https://druglandscape.com/ci/anaferon-for-children. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab